MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Malaria Vaccine Developer Sanaria Inc. and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant, worth nearly $3 million over a 3 year period, will fund research and development to genetically engineer mosquitoes that produce large numbers of parasites for Sanaria’s malaria vaccine manufacturing process.
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission- blocking activity by methylene blue
Clinical studies and mathematical models predict that, to achieve malaria elimination, combination therapies will need to incorporate drugs that block the transmission of Plasmodium falciparum sexual stage parasites to mosquito vectors. Efforts to measure the activity of existing antimalarials on intraerythrocytic sexual stage gametocytes and identify transmission-blocking agents have, until now, been hindered by a lack of quantitative assays. Here, we report an experimental system using P. falciparum lines that stably express gametocyte-specific GFP-luciferase reporters, which enable the assessment of dose- and time-dependent drug action on gametocyte maturation and transmission.
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
Watch the great video!
Initial Trial Of Sanaria’s Malaria Vaccine Yields Positive Results
Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published today in the online issue of Science (www.sciencexpress.org).
Sanaria announces the launch of its Sanaria® Family of Products and Services
Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology.
Peter F. Billingsley PhD, Senior Director of Entomology and Quality Systems, joins Editorial Board of the Malaria Journal
Dr. Billingsley joins a distinguished group of malariologists, in recognition of more than 20 years experience in medical entomology and malaria research. Peter has previously served on the editorial boards of major parasitology and entomology journals, the College of Experts for the Medical Research Council (UK), and advisory boards for mosquito control trials in Africa.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.